The applications of microencapsulated formulation of gliclazide and bile acids in Type-1 diabetes mellitus

QR Code

The applications of microencapsulated formulation of gliclazide and bile acids in Type-1 diabetes mellitus

Gliclazide is used in Type 2 diabetes (T2D) to stimulate insulin production but it also has beneficial extra-pancreatic effects which make it potentially useful in T1D. In this thesis, gliclazide was formulated with different bile acids, to enhance its effects, and formed microcapsules were examined...

Full description

Bibliographic Details
Main Author:	Mathavan, Sangeetha
Format:	Thesis
Published:	Curtin University 2017
Online Access:	http://hdl.handle.net/20.500.11937/59125

Similar Items

Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics
by: Mikov, M., et al.
Published: (2017)

Morphological, Stability, and Hypoglycemic Effects of New Gliclazide-Bile Acid Microcapsules for Type 1 Diabetes Treatment: the Microencapsulation of Anti-diabetics Using a Microcapsule-Stabilizing Bile Acid
by: Mathavan, S., et al.
Published: (2018)

The roles of bile acids and applications of microencapsulation technology in treating Type 1 diabetes mellitus
by: Woodhams, L., et al.
Published: (2017)

The role of the bile acid chenodeoxycholic acid in the targeted oral delivery of the anti-diabetic drug gliclazide, and its applications in type 1 diabetes
by: Mathavan, S., et al.
Published: (2015)

A comprehensive study of novel microcapsules incorporating gliclazide and a permeation enhancing bile acid: hypoglycemic effect in an animal model of Type-1 diabetes
by: Mathavan, Sangeetha, et al.
Published: (2015)

Novel artificial cell microencapsulation of probucol and bile acids in diabetes mellitus
by: Mooranian, Armin
Published: (2018)

Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: A Characterization Study
by: Mooranian, Armin, et al.
Published: (2014)

High-Loading Dose of Microencapsulated Gliclazide Formulation Exerted a Hypoglycaemic Effect on Type 1 Diabetic Rats and Incorporation of a Primary Deconjugated Bile Acid, Diminished the Hypoglycaemic Antidiabetic Effect
by: Golocorbin-Kon, S., et al.
Published: (2017)

Potentials and Limitations of Bile Acids in Type 2 Diabetes Mellitus: Applications of Microencapsulation as a Novel Oral Delivery System
by: Negrulj, Rebecca, et al.
Published: (2013)

Advanced bile acid-based multi-compartmental microencapsulated pancreatic ß-cells integrating a polyelectrolyte-bile acid formulation, for diabetes treatment.
by: Mooranian, A., et al.
Published: (2014)

Diabetes development increased concentrations of the conjugated bile acid, taurocholic acid in serum, while treatment with microencapsulated-taurocholic acid exerted no hypoglycaemic effects
by: Mathavan, S., et al.
Published: (2017)

Stability and Release Kinetics of an Advanced Gliclazide-Cholic Acid Formulation: The Use of Artificial-Cell Microencapsulation in Slow Release Targeted Oral Delivery of Antidiabetics
by: Mooranian, Armin, et al.
Published: (2014)

An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations
by: Mooranian, A., et al.
Published: (2015)

Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats
by: Al-Salami, Hani, et al.
Published: (2012)

Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment
by: Mooranian, Armin, et al.
Published: (2015)

Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics
by: Al-Salami, Hani, et al.
Published: (2008)

An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer
by: Mooranian, Armin, et al.
Published: (2014)

Application of bile acids in drug formulation and delivery
by: Stojancevic, M., et al.
Published: (2014)

A review on the formulation and analysis of anti-diabetic agent: Gliclazide
by: Helal Uddin, A.B.M., et al.
Published: (2013)

The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study
by: Mooranian, A., et al.
Published: (2015)

Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment (vol 32, pg 151, 2014)
by: Mooranian, A., et al.
Published: (2015)

Bile acids for probucol formulations applications in drug induced ototoxicity
by: Ionescu, Corina Mihaela
Published: (2024)

Opportunities for nano-formulations in type 2 diabetes mellitus treatments
by: Jeevanandam, J., et al.
Published: (2015)

Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic ß-cells.
by: Mooranian, Armin, et al.
Published: (2014)

Bile acids and probiotics could help treating diabetes
by: Calasan, J., et al.
Published: (2012)

Development And Evaluation Of A Matrix Controlled-release Formulation Of Gliclazide
by: Adebaibi, Mahmoud
Published: (2008)

Development of type 1 diabetes mellitus blood glucose level simulation mobile application
by: Mohamad Akbar, Asyraf Aiman
Published: (2020)

Innovative platforms for oral microencapsulation formulation and drug analytical techniques for anti-diabetics
by: Gedawy, Ahmed Abou Bakr Gaber
Published: (2020)

Viability and topographical analysis of microencapsulated ß-cells exposed to a biotransformed tertiary bile acid: An ex vivo study
by: Mooranian, Armin, et al.
Published: (2016)

Electrokinetic potential-stabilization by bile acid-microencapsulating formulation of pancreatic ß-cells cultured in high ratio poly-L-ornithine-gel hydrogel colloidal dispersion: applications in cell-biomaterials, tissue engineering and biotechnological applications
by: Mooranian, A., et al.
Published: (2017)

The impact of allylamine-bile acid combinations on cell delivery microcapsules in diabetes
by: Mooranian, Armin, et al.
Published: (2016)

Combination of xanthan gum and HPMC as retardants in sustained release gliclazide formulation
by: Othman, Liyana Zafirah, et al.
Published: (2017)

THE EFFECT OF BILE ACID SALT SODIUM 3ALPHA, 7ALPHA-DIHYDROXY-12-KETO-5BETA-CHOLANATE (MKC) AND PROBIOTIC PRETREATMENT ON GLICLAZIDE PERMEATION IN ILEAL TISSUES FROM HEALTHY AND DIABETIC RATS
by: Mikov, M., et al.
Published: (2014)

Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats
by: Al-Salami, Hani, et al.
Published: (2009)

Bromocriptine for type 2 diabetes mellitus
by: Ooi, Cheow Peng, et al.
Published: (2013)

Quality of life in children and adolescents with type 1 diabetes mellitus in HUSM
by: Nordin, Siti Nuraihan
Published: (2017)

Oral health of children with Type 1 diabetes mellitus: systematic review
by: Ismail, Ahmad Faisal
Published: (2014)

Systematic review of exercise interventions for children with Type 1 diabetes mellitus
by: Cooper, Y., et al.
Published: (2011)

Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and progression of type 1 diabetes
by: Mooranian, Armin, et al.
Published: (2018)

The role of diabetes-associated autoantibodies in confirming the diagnosis of type 1 diabetes mellitus in children and adolescents
by: Gazali, Ahmad Mahfuz
Published: (2023)